Related Experiment Video
Updated: Jun 27, 2026
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
[Effects of piperazine ferulate on TGF-beta1-induced renal interstitial fibroblast activation]
Guan-qiao You1, Ping Fu, Xi-sheng Xie
1Department of Nephrology, West China Hospital, Sichuan University, Chengdu 610041, China.
Objective:
To investigate the effects of piperazine ferulate (PF) on TGF-beta1-induced renal interstitial fibroblast activation, and to explore the mechanism of PF in the prevention of renal tubulointerstitial fibrosis.
Methods:
In cultured normal rat renal kidney fibroblast (NRK-49F), the effect of PF on the TGF-beta1-induced cell vitality was observed by MTT. The protein expression levels of a-smooth muscle actin (alpha-SMA), connective tissue growth factor (CTGF) induced by TGF-beta1 were evaluated by immunocytochemistry. The levels of a-SMA, CTGF mRNA expression induced by TGF-beta1, were determined by quantitative real time fluroscent polymerase chain reaction. The levels of collagen type I (Col I) and fibronectin (FN) protein expression were examined by Enzyme Linked Immunosorbent Assay(ELISA).
Results:
TGF-beta1 may markedly increase the cell vitality, alpha-SMA and CTGF expression, FN and Col I protein expression (P < 0.05). Compared with TGF-beta1-induced group, PF can partly decrease the cell vitality, level of alpha-SMA and CTGF expression and extracellular matrix(ECM) synthesis induced by TGF-beta1 (P < 0.05).
Conclusion:
PF may inhibit TGF-beta1-induced fibrosis in the renal fibroblast to a certain extent.
Insights
Piperazine ferulate (PF) partially inhibits transforming growth factor-beta1 (TGF-β1)-induced renal fibroblast activation and extracellular matrix synthesis, suggesting a potential role in preventing renal tubulointerstitial fibrosis.
Area of Science:
- Nephrology
- Pharmacology
- Cell Biology
Background:
- Renal tubulointerstitial fibrosis is a key pathological process in chronic kidney disease progression.
- Transforming growth factor-beta1 (TGF-β1) is a critical mediator of fibroblast activation and extracellular matrix (ECM) deposition.
- Identifying novel therapeutic agents to inhibit renal fibrosis is of significant clinical importance.
Purpose of the Study:
- To investigate the inhibitory effects of piperazine ferulate (PF) on TGF-β1-induced activation of renal interstitial fibroblasts.
- To explore the underlying mechanism by which PF may prevent renal tubulointerstitial fibrosis.
Main Methods:
- Normal rat renal kidney fibroblast (NRK-49F) cells were treated with TGF-β1 and varying concentrations of PF.
- Cell vitality was assessed using MTT assays.
- Protein and mRNA expression of alpha-smooth muscle actin (α-SMA) and connective tissue growth factor (CTGF) were measured by immunocytochemistry and quantitative real-time PCR, respectively.
- Extracellular matrix components, collagen type I (Col I) and fibronectin (FN), were quantified using ELISA.
Main Results:
- TGF-β1 significantly increased NRK-49F cell vitality, α-SMA, CTGF expression, and ECM synthesis (Col I, FN) (P < 0.05).
- PF treatment partially attenuated TGF-β1-induced increases in cell vitality, α-SMA and CTGF expression, and ECM synthesis (P < 0.05).
Conclusions:
- Piperazine ferulate demonstrates a partial inhibitory effect on TGF-β1-induced fibrosis in renal fibroblasts.
- PF may represent a potential therapeutic strategy for mitigating renal tubulointerstitial fibrosis.
